Pulmonary Arterial Hypertension (PAH) Market Estimates, Share,
Vendors, Growth Rate Forecast 2014-2025
“Pulmonary Arterial Hypertension (PAH) Market size was valued at USD 5.0
billion in 2015 and is anticipated to reach USD 8.7 billion by 2025. Pulmonary
arterial hypertension (PAH) is a type of high blood pressure that occurs in the
right side of the heart and in the arteries that supply blood to the lungs.”
The global Pulmonary Arterial Hypertension (PAH) Market size was valued at USD 5.0 billion in 2015 and is
anticipated to reach USD 8.7 billion by 2025. Pulmonary arterial hypertension (PAH) is a type of high blood
pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. These
arteries are called pulmonary arteries. PAH occurs when the pulmonary arteries thicken or grow rigid. PAH is
one of the five groups of pulmonary hypertension, classified by the World Health Organization (WHO).The
market for PAH is growing moderately due to newer launches of pipeline drugs that target different pathways
to suppress the symptoms of the disease. Early diagnosis of the disease has played a pivotal role in number of
patients undergoing treatment.
Globally the PAH market is segmented on the basis of Drug class, Surgery, and region. On the basis of Drug class,
the global PAH market is classified into Endothelin Receptor Antagonists (ERAs) (Tracleer, Opsumit, Letairis)-
These medications reverse the effect of endothelin, a substance in the walls of blood vessels that causes them
to narrow; Prostacyclin and Prostacyclin Analogs- were the first medications approved by the U.S. FDA for the
treatment of PAH. Phosphodiesterase-5 (PDE-5) V Inhibitors, Sildenafil, and Tadalafil- Revatio, Viagra, Cialis, etc.
These drugs work by opening the blood vessels in the lungs to allow blood to flow easily. These drugs have
superiority over existing therapy options with respect to the therapeutic efficacy, route of administration, and
side-effects.
Request Sample Copy of this Market Research @
https://www.millioninsights.com/industry-reports/pulmonary-arterial-hypertension-pah-market/request-sample